1-ethoxy-1-methylcyclohexane | 138710-81-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-ethoxy-1-methylcyclohexane
• CAS: 138710-81-3
• 化学式: C₉H₁₈O
• 分子量: 142.241
• InChiKey: PUBZQGPQICKOBY-UHFFFAOYSA-N

物化性质

• 沸点：
  158.7±8.0 °C(Predicted)
• 密度：
  0.86±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  环己酮 在 硫酸 作用下， 反应 60.0h， 生成 1-ethoxy-1-methylcyclohexane
  参考文献：
  名称：

  Beger, J.; Thomas, B.; Vogel, T., Journal fur praktische Chemie (Leipzig 1954), 1991, vol. 333, # 3, p. 481 - 488

  摘要：

  DOI：

文献信息

• Microwave Mediated Protection of Hindered Phenols and Alcohols
  作者：Tejas Pothi、Mahesh Dawange、Kamlesh Chavan、Rajiv Sharma、Nabajyoti Deka

  DOI：10.5012/jkcs.2012.56.6.706

  日期：2012.12.20

  Hindered phenols and alcohols were protected as their corresponding ethers using different alkylating agents in presence of KOH/DMSO under microwave irradiation. $$R-OH\;KOH/DMSO,\;R^\prime}-X,\;MW \\\vec10-15\;Mins,\;80%-90%\;Yield}}}\;R^/}^O\backslash}}R^\prime}$$.

  在微波照射下，使用不同的烷基化试剂，在KOH/DMSO的存在下，将 hindered 酚和醇保护为其相应的醚。$$R-OH\;KOH/DMSO,\;R^\prime}-X,\;MW \\\vec10-15\;Mins,\;80%-90%\;Yield}}}\;R^/}^O\backslash}}R^\prime}$$.
• QUATERNARY AMMONIUM SALT COMPOUND, COMPOSITION FOR FORMING A RESIST UNDER LAYER FILM, AND PATTERNING PROCESS
  申请人：SHIN-ETSU CHEMICAL CO., LTD.

  公开号：US20150357204A1

  公开（公告）日：2015-12-10

  A quaternary ammonium salt compound is represented by the following formula (A-1), wherein, R 1 , R 2 , and R 3 each represent an alkyl group, an alkenyl group, an aryl group, or an aralkyl group, a part or all of hydrogen atoms in these groups may be substituted by a hydroxyl group(s), an alkoxy group(s), or a halogen atom(s), and these groups may include one or more of a carbonyl group and an ester bond; R 4 represents a single bond, an alkylene group, an alkenylene group, an arylene group, or an aralkylene group, a part or all of hydrogen atoms in these groups may be substituted by an alkoxy group(s) or a halogen atom(s), and these groups may include one or more of an ether bond, a carbonyl group, an ester bond, and an amide bond; and A − represents a non-nucleophilic counter ion.

  一个四元铵盐化合物由以下式（A-1）表示，其中，R1、R2和R3分别代表烷基、烯基、芳基或芳基烷基，这些基团中的氢原子的一部分或全部可以被羟基、烷氧基或卤原子取代，这些基团中可能包括一个或多个羰基和酯键；R4代表一个单键、烷基、烯基、芳基或芳基烷基，这些基团中的氢原子的一部分或全部可以被烷氧基或卤原子取代，这些基团中可能包括一个或多个醚键、羰基、酯键和酰胺键；A−代表一个非亲核对离子。
• [EN] BENZAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE BENZAMIDE EN TANT QU'ANTAGONISTES DU RÉCEPTEUR P2X7
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2012114268A1

  公开（公告）日：2012-08-30

  The invention relates to benzamide derivatives of formula (I),wherein R1, R2, R3, R4, R5, R6, n and Y are as defined in the description, their preparation and their use as pharmaceutically active compounds.

  该发明涉及公式（I）中的苯甲酰胺衍生物，其中R1、R2、R3、R4、R5、R6、n和Y如描述中所定义，它们的制备以及它们作为药用活性化合物的用途。
• Heterocyclic antiviral compounds
  申请人：Rotstein David Mark

  公开号：US20090281133A1

  公开（公告）日：2009-11-12

  This invention relates to piperidine derivatives of formula I wherein R 1 , R 2 and R 3 are as defined herein useful in the treatment of a variety of disorders, including those in which the modulation of CCR5 receptors is implicated. Disorders that may be treated or prevented by the present derivatives include HIV and genetically related retroviral infections (and the resulting acquired immune deficiency syndrome, AIDS), rheumatoid arthritis, solid organ transplant reject (graft vs. host disease), asthma and COPR.

  本发明涉及公式I的哌啶衍生物，其中R1，R2和R3如本文所定义，可用于治疗多种疾病，包括涉及CCR5受体调节的疾病。当前衍生物可用于治疗或预防的疾病包括HIV和遗传相关的逆转录病毒感染（及由此引起的获得性免疫缺陷综合症，艾滋病），类风湿性关节炎，实体器官移植排斥（移植物抗宿主病），哮喘和COPR。
• COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM
  申请人：Takayama Masami

  公开号：US20090318513A1

  公开（公告）日：2009-12-24

  A compound represented by the general formula (I): wherein R 1 is a hydrogen atom, a halogen atom, or the like; R 2 , R 3 , and R 4 are each independently a hydrogen atom, a halogen atom, C1-C15 alkyl optionally substituted with one or more C1-C12 alkyloxy or the like, or the like; R 5 is a hydrogen atom or the like; R 6 and R 7 are a hydrogen atom or the like; R 8 is C1-C3 alkyl or the like; R 9 is a hydrogen atom or the like), a prodrug, a pharmaceutically acceptable salt, or solvate thereof.

  一种由通式（I）表示的化合物：其中R1是氢原子、卤素原子或类似物；R2、R3和R4各自独立地是氢原子、卤素原子、C1-C15烷基（可选地用一个或多个C1-C12烷氧基或类似物取代）或类似物；R5是氢原子或类似物；R6和R7是氢原子或类似物；R8是C1-C3烷基或类似物；R9是氢原子或类似物。该化合物为一种前药、药物可接受的盐或其溶剂。